{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:45:16Z","timestamp":1784090716088,"version":"3.55.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,7,16]]},"abstract":"<jats:p>\n            The use of carbapenem antibiotics to treat infections caused by\n            <jats:italic>Enterobacterales<\/jats:italic>\n            expressing increasingly aggressive extended-spectrum \u03b2-lactamases (ESBLs) has contributed to the emergence of carbapenem resistance. Enmetazobactam is a novel ESBL inhibitor being developed in combination with cefepime as a carbapenem-sparing option for infections caused by ESBL-producing\n            <jats:italic>Enterobacterales<\/jats:italic>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.00926-21","type":"journal-article","created":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T22:38:48Z","timestamp":1623623928000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Sigmoid\n            <i>E<\/i>\n            <sub>max<\/sub>\n            Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-9446","authenticated-orcid":true,"given":"Philipp","family":"Knechtle","sequence":"first","affiliation":[{"name":"Allecra Therapeutics SAS, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Morrissey","sequence":"additional","affiliation":[{"name":"IHMA Europe S\u00e0rl, Monthey, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyntia","family":"De Piano","sequence":"additional","affiliation":[{"name":"IHMA Europe S\u00e0rl, Monthey, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5090-5938","authenticated-orcid":true,"given":"Adam","family":"Belley","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis.","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. WHO, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914433"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1660772"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx181"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.02.031"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.05.001"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1478"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105925"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-20"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00180-20"},{"key":"e_1_3_2_15_2","volume-title":"Outcomes of the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination of cefepime-enmetazobactam versus piperacillin-tazobactam in adult patients with complicated urinary tract infections \u2013 the ALLIUM phase 3 trial.","author":"Kaye KS","year":"2020","unstructured":"Kaye KS, Belley A, Lahlou O, Barth P, Motta P, Kashyap S, Knechtle P, Velicitat P. 2020. Outcomes of the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination of cefepime-enmetazobactam versus piperacillin-tazobactam in adult patients with complicated urinary tract infections \u2013 the ALLIUM phase 3 trial. abstr 30th European Congress of Clinical Microbiology and Infectious Disease, 18 to 21 April 2020, Paris, France."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00223-18"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.11.025"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01377.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00607-19"},{"key":"e_1_3_2_22_2","volume-title":"Pharmacodynamic evaluation of AAI101, a novel extended-spectrum beta-lactamase inhibitor (BLI). Combination with Cefepime in Hollow Fiber Models of ESBL Enterobacterial Infection","author":"Louie A","year":"2015","unstructured":"Louie A, Robbins N, Kurhanewicz S, Fikes S, Liu W, Baluya D, Brown D, Shapiro S, Pypstra R, Drusano G. 2015. Pharmacodynamic evaluation of AAI101, a novel extended-spectrum beta-lactamase inhibitor (BLI). Combination with Cefepime in Hollow Fiber Models of ESBL Enterobacterial Infection, abstr 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17 to 21 September 2014, San Diego, CA."},{"key":"e_1_3_2_23_2","volume-title":"Performance standards for antimicrobial susceptibility testing.","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2019","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2019. Performance standards for antimicrobial susceptibility testing. 29th ed, CLSI supplement M100. CLSI, Wayne PA, USA.","edition":"29"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02804-z"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01580-16"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02513-12"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02309-18"},{"key":"e_1_3_2_29_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201310th ed, M07-A10.","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201310th ed, M07-A10. CLSI, Wayne PA, USA."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-33706-7_9"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2009.182"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00926-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00926-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:00:59Z","timestamp":1645484459000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00926-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,7,16]]}},"alternative-id":["10.1128\/AAC.00926-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00926-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"2021-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00926-21"}}